EXSCIENTIA PLC (EXAI) Stock Price & Overview
NASDAQ:EXAI • US30223G1022
Current stock price
The current stock price of EXAI is 4.84 USD. Today EXAI is up by 3.2%. In the past month the price decreased by -4.16%. In the past year, price decreased by -21.94%.
EXAI Key Statistics
- Market Cap
- 633.177M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.65
- Dividend Yield
- N/A
EXAI Stock Performance
EXAI Stock Chart
EXAI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to EXAI. When comparing the yearly performance of all stocks, EXAI is a bad performer in the overall market: 87.66% of all stocks are doing better.
EXAI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EXAI. EXAI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
EXAI Earnings
On November 8, 2024 EXAI reported an EPS of -0.36 and a revenue of 5.60M. The company missed EPS expectations (-216.45% surprise) and missed revenue expectations (-57.12% surprise).
EXAI Forecast & Estimates
8 analysts have analysed EXAI and the average price target is 5.46 USD. This implies a price increase of 12.75% is expected in the next year compared to the current price of 4.84.
For the next year, analysts expect an EPS growth of 42.38% and a revenue growth 63.9% for EXAI
EXAI Groups
Sector & Classification
EXAI Financial Highlights
Over the last trailing twelve months EXAI reported a non-GAAP Earnings per Share(EPS) of -1.65. The EPS increased by 5.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.37% | ||
| ROE | -36.43% | ||
| Debt/Equity | 0.05 |
EXAI Ownership
EXAI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.82 | 364.65B | ||
| AMGN | AMGEN INC | 15.24 | 188.631B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 175.177B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.42 | 116.358B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.68 | 77.963B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.84 | 41.258B | ||
| INSM | INSMED INC | N/A | 31.039B | ||
| NTRA | NATERA INC | N/A | 28.733B | ||
| BIIB | BIOGEN INC | 11.29 | 26.917B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.55 | 23.098B | ||
| MRNA | MODERNA INC | N/A | 20.683B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 19.837B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.676B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EXAI
Company Profile
Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company is headquartered in Oxford, Oxfordshire and currently employs 483 full-time employees. The company went IPO on 2021-10-01. The firm combines precision design with integrated experimentation to invent and develop drugs. The company uses artificial intelligence (AI) in drug discovery to progress AI-designed small molecules into a clinical setting. The company uses the patient's tissue data to define optimal profiles for research, improve experimental assessment during design and improve outcomes in a medical setting. The company has developed an internal pipeline focused on oncology, while its partnered pipeline extends to various other therapeutic areas. The company combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The firm's experimental platform records responses in real patient samples allowing it to generate high-precision views of potential patient response. Its product pipeline consists of GTAEXS617, EXS4318, EXS74539, and EXS73565.
Company Info
IPO: 2021-10-01
EXSCIENTIA PLC
The Schrodinger Building, Oxford Science Park
Oxford OXFORDSHIRE GB
Employees: 483
Phone: 441865818941
EXSCIENTIA PLC / EXAI FAQ
What does EXAI do?
Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company is headquartered in Oxford, Oxfordshire and currently employs 483 full-time employees. The company went IPO on 2021-10-01. The firm combines precision design with integrated experimentation to invent and develop drugs. The company uses artificial intelligence (AI) in drug discovery to progress AI-designed small molecules into a clinical setting. The company uses the patient's tissue data to define optimal profiles for research, improve experimental assessment during design and improve outcomes in a medical setting. The company has developed an internal pipeline focused on oncology, while its partnered pipeline extends to various other therapeutic areas. The company combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The firm's experimental platform records responses in real patient samples allowing it to generate high-precision views of potential patient response. Its product pipeline consists of GTAEXS617, EXS4318, EXS74539, and EXS73565.
What is the stock price of EXSCIENTIA PLC today?
The current stock price of EXAI is 4.84 USD. The price increased by 3.2% in the last trading session.
What is the dividend status of EXSCIENTIA PLC?
EXAI does not pay a dividend.
What is the ChartMill rating of EXSCIENTIA PLC stock?
EXAI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for EXAI stock?
EXSCIENTIA PLC (EXAI) currently has 483 employees.
Who owns EXSCIENTIA PLC?
You can find the ownership structure of EXSCIENTIA PLC (EXAI) on the Ownership tab.